See more : Bengal Energy Ltd. (BNGLF) Income Statement Analysis – Financial Results
Complete financial analysis of CorMedix Inc. (CRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CorMedix Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TheMaven, Inc. (MVEN) Income Statement Analysis – Financial Results
- Renault SA (RNSDF) Income Statement Analysis – Financial Results
- Instructure Holdings, Inc. (INST) Income Statement Analysis – Financial Results
- Sartorius Stedim Biotech S.A. (SRTOY) Income Statement Analysis – Financial Results
- Pluri Inc. (PLUR) Income Statement Analysis – Financial Results
CorMedix Inc. (CRMD)
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 65.41K | 190.94K | 239.23K | 283.27K | 429.80K | 329.33K | 224.11K | 210.13K | 189.27K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 205.56K | 3.73K | 148.94K | 204.85K | 373.23K | 396.79K | 114.96K | 366.67K | 318.72K | 445.80K | 201.61K | 0.00 | 0.00 | 0.00 | 0.00 | 1.04M |
| Gross Profit | -205.56K | 61.67K | 42.00K | 34.39K | -89.97K | 33.01K | 214.36K | -142.57K | -108.59K | -256.53K | -199.60K | 0.00 | 0.00 | 0.00 | 0.00 | -1.04M |
| Gross Profit Ratio | 0.00% | 94.29% | 22.00% | 14.37% | -31.76% | 7.68% | 65.09% | -63.62% | -51.68% | -135.53% | -9,975.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.16M | 10.68M | 13.13M | 13.38M | 11.05M | 18.82M | 24.49M | 15.74M | 6.28M | 1.32M | 1.23M | 1.19M | 4.10M | 5.49M | 4.89M | 3.08M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.80M | 20.01M | 16.35M | 13.88M | 9.87M | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 691.89K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.96M | 30.69M | 29.48M | 27.26M | 20.92M | 26.90M | 33.14M | 24.62M | 16.55M | 8.65M | 4.72M | 3.04M | 7.25M | 8.51M | 6.06M | 3.77M |
| Cost & Expenses | 48.96M | 30.69M | 29.48M | 27.46M | 21.29M | 27.29M | 33.25M | 24.99M | 16.86M | 9.09M | 4.92M | 3.04M | 7.25M | 8.51M | 6.06M | 4.82M |
| Interest Income | 0.00 | 326.02K | 14.40K | 116.07K | 322.67K | 36.62K | 110.71K | 126.77K | 60.39K | 2.71K | 668.00 | 1.97K | 12.04K | 23.44K | 2.13K | 25.90K |
| Interest Expense | 0.00 | 26.52K | 15.94K | 33.23K | 787.49K | 1.87K | 5.62K | 1.31K | 3.96K | 2.09K | 1.44M | 382.94K | 12.04K | 3.09M | 2.07M | 4.21M |
| Depreciation & Amortization | 70.76K | 209.04K | 177.02K | 143.49K | 73.29K | 74.22K | 36.89K | 25.60K | 15.08K | 15.07K | 5.16K | 7.02K | 12.25K | 12.17K | 9.95K | 1.04M |
| EBITDA | -48.89M | -30.05M | -29.38M | -27.02M | -20.63M | -26.75M | -32.97M | -24.62M | -18.17M | -20.44M | -7.68M | -3.04M | -7.19M | -8.47M | -6.04M | -3.75M |
| EBITDA Ratio | 0.00% | -46,321.48% | -15,421.12% | -11,329.92% | -7,302.40% | -6,241.92% | -9,963.77% | -10,980.81% | -7,889.64% | -4,693.90% | -245,581.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.96M | -30.62M | -29.44M | -27.22M | -21.01M | -26.86M | -32.92M | -24.76M | -16.65M | -8.90M | -4.92M | -3.04M | -7.25M | -8.51M | -6.06M | -4.82M |
| Operating Income Ratio | 0.00% | -46,819.91% | -15,417.51% | -11,378.44% | -7,416.31% | -6,250.44% | -9,997.39% | -11,048.80% | -7,925.56% | -4,703.30% | -245,646.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.62M | 336.65K | -22.83K | 23.67K | -485.98K | 34.57K | -85.80K | 117.29K | -1.53M | -11.55M | -4.22M | -380.97K | 41.86K | -2.68M | -2.07M | -4.18M |
| Income Before Tax | -46.34M | -30.29M | -29.46M | -27.20M | -21.49M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -7.21M | -11.19M | -8.12M | -9.00M |
| Income Before Tax Ratio | 0.00% | -46,305.23% | -15,429.47% | -11,368.54% | -7,587.87% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -585.62K | -1.25M | -5.17M | -5.06M | 36.44K | -31.27K | 1.31K | 3.96K | 2.09K | 1.44M | 1.97K | -493.86K | -280.92K | 2.13K | 0.00 |
| Net Income | -46.34M | -29.70M | -28.21M | -22.03M | -16.43M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -6.71M | -10.91M | -8.12M | -9.00M |
| Net Income Ratio | 0.00% | -45,409.90% | -14,774.70% | -9,207.70% | -5,801.29% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| EPS Diluted | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| Weighted Avg Shares Out | 50.90M | 40.14M | 37.61M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.90M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
CorMedix Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10
BERKELEY HEIGHTS, N.J. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report...
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference
BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been...
CorMedix Inc. (CRMD) CEO Joseph Todisco on Q2 2022 Results - Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors, LLC Erin Mistry - Senior Vice President and Head, Payer Strategy, Government Affairs and Trade Joseph Todisco -...
CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Conference Call Scheduled for Today at 8:30 a.m. Eastern Time
Why CorMedix Stock Was Plummeting on Tuesday
Bad news on the regulatory front leads investors to bail en masse from the company.
CorMedix to Participate at the JMP Securities Life Sciences Conference
BERKELEY HEIGHTS, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be participating...
CorMedix Inc. (CRMD) CEO Joe Todisco on Q1 2022 Results - Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Daniel Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry...
CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time
CorMedix Inc. Announces Leadership Updates and Operational Changes
BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its leadership team...
Source: https://incomestatements.info
Category: Stock Reports